ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1871

Progranulin Directly Binds To The CRD 2 and CRD3 Of TNFR Extracellular Domains

Jinlong Jian1, Shuai Zhao1, Qingyun Tian1, Elena Gonzalez Gugel2, Jyoti Mundra2, Sardar MZ Uddin2, Ben Liu3, Brendon Richbourgh2, Ryan Brunetti2, Gerald Chan4, Carolyn Green5 and Chuanju Liu1, 1Orthopaedic Surgery, NYU Hospital for Joint Diseases, New York, NY, 2NYU Hospital for Joint Diseases, New York, NY, 3NYU Hospital for Joint Diseases, New York Univerity, NY, 4Atreaon, Boston, MA, 5Atreaon, Boston, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: We previously reported that Progranulin (PGRN) bound to TNF receptors (TNFR) and was therapeutic in inflammatory arthritis (Tang, W., et al, Science, 2011). PGRN is highly cysteine-rich glycoprotein, and contains a number of internal disulfide bonds, which are critical for maintaining the proper folding and confirmation of this protein. The objective of this project is 1) to determine whether PGRN also form a complex with TNFR in immune cells, and whether PGRN affects the binding of TNFα to immune cells, 2) to compare the effects of folding of PGRN on its binding to TNFR and Sortilin, a neuronal receptor known to interact with PGRN as well, and 3) to dissect and identify the domains of TNFR required for PGRN interaction.

Methods: Co-Immunoprecipitation (CoIP) assay and TNF-α blocking assay with flow cytometry were performed to examine the association of PGRN and TNFR in immune cells and its inhibition of TNF binding to cell surface; Various protein-protein interaction assays, including Solid phase binding, Surface Plasmon Resonance, yeast-two hybrid and GST pull-down, were performed to compare the binding activity of various sources of PGRN, to determine the effects of folding of PGRN to TNFR, and to identify the domains of TNFR responsible for binding to PGRN; Differentiation of bone marrow-derived macrophages were used to measure the biological activity of PGRN with ELISA and real-time PCR.

Results: Our previous study showed that PGRN bound to TNFR in chondrocytes. Here we found that PGRN also associated with TNFR2 in splenocytes in a Co-IP assay, and PGRN blocked the binding of TNFα to splenocytes in a dose-dependent manner.

Proper folding and modification of PGRN appear to be essential for its binding to TNFR, as DTT treatment, which is known to disturb the formation of disulfide bonds in PGRN and in turn affects its folding, abolished its binding to TNFR. Interestingly, the binding of PGRN to Sortilin was actually enhanced by DTT treatment. This is probably due to the fact that the C-terminal last three amino acids (DLL) of PGRN, known to be required for Sortilin binding, are exposed in the unfolded PGRN and become more easily accessible to Sortilin. Additionally, in vitro direct protein interaction assays, including Solid phase and Surface Plasmon Resonance, and cell-based functional assays revealed 1) that some commercial PGRNs are of poor quality, and that 2) the selection of chips in Surface Plasmon Resonance is important for demonstrating the high affinity binding of PGRN to TNFR.

Yeast two hybrid assays with numerous deletion mutants of TNFR extracellular domain demonstrated that CRD2 and CRD3 of TNFR are important for the interaction with PGRN, similar to its binding to their canonical ligand TNFα. This finding was confirmed with in vitro GST pulldown and solid phase assay with recombinant proteins.

Conclusion: These findings provide the molecular basis underlying PGRN-mediated anti-inflammatory activity in various autoimmune diseases and conditions.


Disclosure:

J. Jian,
None;

S. Zhao,
None;

Q. Tian,
None;

E. G. Gugel,
None;

J. Mundra,
None;

S. M. Uddin,
None;

B. Liu,
None;

B. Richbourgh,
None;

R. Brunetti,
None;

G. Chan,
None;

C. Green,

Atreaon Inc. ,

3;

C. Liu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/progranulin-directly-binds-to-the-crd-2-and-crd3-of-tnfr-extracellular-domains/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology